Grace Therapeutics, Inc (GRCE)

Currency in USD
2.1600
+0.0900(+4.35%)
Closed·
2.16000.0000(0.00%)
·
GRCE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.02002.1900
52 wk Range
1.79005.1800
Key Statistics
Prev. Close
2.07
Open
2.06
Day's Range
2.02-2.19
52 wk Range
1.79-5.18
Volume
397.81K
Average Volume (3m)
265.43K
1-Year Change
-33.7423%
Book Value / Share
2.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GRCE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.0570
Upside
+180.42%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Grace Therapeutics, Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.0570
(+180.42% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy4.00+85.19%11.00MaintainApr 24, 2026
TD Cowen
Buy8.00+270.37%12.00MaintainApr 23, 2026

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.91 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GRCE Income Statement

Compare GRCE to Peers and Sector

Metrics to compare
GRCE
Peers
Sector
Relationship
P/E Ratio
−2.2x7.3x−0.4x
PEG Ratio
0.04−0.210.00
Price/Book
0.9x3.4x2.6x
Price / LTM Sales
-2.2x3.1x
Upside (Analyst Target)
180.4%488.9%48.3%
Fair Value Upside
Unlock3.5%6.2%Unlock

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
477.12K2.93%1.03M
Other Institutional Investors
9.48M58.23%20.47M
Public Companies & Retail Investors
6.32M38.84%13.65M
Total
16.27M100.00%35.15M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Opaleye Management Inc.13.07%2,748,3925,937
Opaleye L.P13.07%2,748,3925,937

People Also Watch

100.50
EPAM
-1.03%
81.640
AXTI
+5.41%
11.53
XNDU
+6.96%
140.00
SPCX
-0.91%
2.250
CMPX
-0.44%

FAQ

What Is the Grace Therapeutics, (GRCE) Stock Price Today?

The Grace Therapeutics, stock price today is 2.1600 USD.

What Stock Exchange Does Grace Therapeutics, Trade On?

Grace Therapeutics, is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Grace Therapeutics,?

The stock symbol for Grace Therapeutics, is "GRCE."

What Is the Grace Therapeutics, Market Cap?

As of today, Grace Therapeutics, market cap is 45.4400M USD.

What Is Grace Therapeutics,'s Earnings Per Share (TTM)?

The Grace Therapeutics, EPS (TTM) is -1.2003.

From a Technical Analysis Perspective, Is GRCE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Grace Therapeutics, Stock Split?

Grace Therapeutics, has split 3 times.

How Many Employees Does Grace Therapeutics, Have?

Grace Therapeutics, has 5 employees.

What is the current trading status of Grace Therapeutics, (GRCE)?

As of Aug 16, 2026, Grace Therapeutics, (GRCE) is trading at a price of 2.1600 USD, with a previous close of 2.0700 USD. The stock has fluctuated within a day range of 2.0200 USD to 2.1900 USD, while its 52-week range spans from 1.7900 USD to 5.1800 USD.

What Is Grace Therapeutics, (GRCE) Price Target According to Analysts?

The average 12-month price target for Grace Therapeutics, is 6.0570 USD, with a high estimate of 8.02652443 USD and a low estimate of 4.0875018 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +180.42% Upside potential.

What Is the GRCE Premarket Price?

GRCE's last pre-market stock price is 2.1100 USD. The pre-market share volume is 150.0000, and the stock has decreased by 0.0400, or 1.9300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.